Research and Markets: Novel Antibodies & Therapeutic Proteins: Technological Challenges & Future Prospects

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/fbbbf9/novel_antibodies) has announced the addition of the "Novel Antibodies & Therapeutic Proteins: Technological Challenges & Future Prospects" report to their offering.

This innovative & analytical report can be used to assess market trends & appraise the potential of new antibodies & therapeutic proteins. It provides perspective to:

  • Gain an in-depth understanding of the marketplace, players, products & leading technologies driving the field;
  • Evaluate the unmet clinical needs, product pipelines & technological challenges for the next generation of mAbs & TPs;
  • Identify the key regulatory, IP & reimbursement issues which face biopharmaceutical companies;
  • Assess the therapeutic potential of new mAbs & TPs targeting cancer, immuno-inflammatory related disorders, CNS disorders & others;
  • Identify the potential threat of biosimilars & examine their impact on the prescription & development of new biologics now & in the future;
  • Analyze the market trends & highlight future market opportunities.

KEY FINDINGS:

  • From the 1990s onwards, growing insight into the biological processes responsible for disease led to a drive to develop treatments based on the biological contributors to in disease processes. Thus, began the biopharmaceutical era, and an accompanying shift of focus to large-molecule compounds.
  • The biopharmaceutical market is now estimated to be worth over US$78 billion in 2009 growing by 15% per annum, focusing on two key areas, monoclonal antibodies and biological active proteins and driven by advances in biotechnology, manufacturing and delivery.
  • mAbs have been widely used to treat cancer and immuno-inflammatory related diseases; promising new treatments are under development. Abbott Laboratories, Bristol-Myers Squibb, Johnson & Johnson and Biogen Idec and Genentech, dominate the market; several other companies have promising pipelines including: Amgen, BioInvent International AB, Celldex Therapeutics, Genmab A/S, Glycotope GmbH, ImmunoGen, Pfizer, Seattle Genetics, Tolerx and Wilex AG.
  • TPs have been widely used to treat a wide range of diseases including: diabetes, growth hormone deficiencies, blood disorders, immuno-inflammatory related diseases. Numerous products are under development for these and other conditions, such as cancer and gastrointestinal disorders.
  • The introduction of recombinant DNA technologies and genetic engineering has revolutionized the production of mAb and TPs. The modification of antibody mediated techniques (phage display) and the adoption of high throughput screening technologies has improved productivity and the reproducibility of complex proteins, which is central to discovery and characterisation of new TPs.
  • and much more.....

Key Topics Covered:

  • Key Findings
  • Chapter 1 Introduction: Historical Milestones & Impact on the Pharma Industry
  • Chapter 2 Monoclonal Antibodies: Market Segmentation, Size & Trends
  • Chapter 3 Therapeutic Proteins: Market Segmentation, Size & Trends
  • Chapter 4 Challenges & Advances in Discovery, Development & Commercialization of TPs
  • Chapter 5 Regulation, IP & Reimbursement Issues
  • Chapter 6 Industry Perspective & Future Prospects
  • List of Figures
  • List of Tables

For more information visit http://www.researchandmarkets.com/research/fbbbf9/novel_antibodies



CONTACT:

Research and Markets
Laura Wood, Senior Manager
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.